Skip to main content
Premium Trial:

Request an Annual Quote

New Products: New Antibody Technology from Morphosys and More

Premium

Morphosys this week presented its new antibody technology Ylanthia, the next generation of the company’s HuCAL platform.

According to the company, Ylanthia is the industry’s largest fragment antigen binding library, comprising more than 100 billion distinct human antibodies, with all antibodies pre-selected for expression levels, stability, and aggregation behavior. The company optimizes the Ylanthia library with its Slonomics technology, which, it said, offers improved speed and flexibility compared to its HuCAL line.


Gentel this week launched its new Colony Surveillance Assays for monitoring specific pathogen-free status in nonhuman primates.

The panel uses Gentel’s Proteomics Multi-System and tests for 11 infectious agents including rhesus rhadinovirus and spumavirus simian foamy virus.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.